Abstract
Context
Large variations exist among hospitals in the use of treatment resources for community-acquired pneumonia (CAP). Lack of a common approach to the diagnosis and treatment of CAP has been cited as an explanation for these variations.Objective
To determine if use of a critical pathway improves the efficiency of treatment for CAP without compromising the well-being of patients.Design
Multicenter controlled clinical trial with cluster randomization and up to 6 weeks of follow-up.Setting
Nineteen teaching and community hospitals in Canada.Patients
A total of 1743 patients with CAP presenting to the emergency department at 1 of the participating institutions between January 1 and July 31, 1998.Intervention
Hospitals were assigned to continue conventional management (n = 10) or implement the critical pathway (n = 9), which consisted of a clinical prediction rule to guide the admission decision, levofloxacin therapy, and practice guidelines.Main outcome measures
Effectiveness of the critical pathway, as measured by health-related quality of life on the Short-Form 36 Physical Component Summary (SF-36 PCS) scale at 6 weeks; and resource utilization, as measured by the number of bed days per patient managed (BDPM).Results
Quality of life and the occurrence of complications, readmission, and mortality were not different for the 2 strategies; the 1-sided 95% confidence limit of the between-group difference in the SF-36 PCS change score was 2.4 points, which was within a predefined 3-point boundary for equivalence. Pathway use was associated with a 1.7-day reduction in BDPM (4.4 vs 6.1 days; P = .04) and an 18% decrease in the admission of low-risk patients (31% vs 49%; P = .01). Although inpatients at critical pathway hospitals had more severe disease, they required 1.7 fewer days of intravenous therapy (4.6 vs 6.3 days; P = .01) and were more likely to receive treatment with a single class of antibiotic (64% vs 27%; P<.001).Conclusion
In this study, implementation of a critical pathway reduced the use of institutional resources without causing adverse effects on the well-being of patients.Citations & impact
Impact metrics
Article citations
The impact of hospital-specific guidelines on carbapenem use and patient outcomes in a setting for high endemicity with multidrug-resistant gram-negative bacilli.
Antimicrob Steward Healthc Epidemiol, 4(1):e146, 25 Sep 2024
Cited by: 0 articles | PMID: 39346671 | PMCID: PMC11428004
Prognostic clinical decision support for pneumonia in the emergency department: A randomized trial.
J Hosp Med, 19(9):802-811, 26 May 2024
Cited by: 0 articles | PMID: 38797872
Early machine learning prediction of hospitalized patients at low risk of respiratory deterioration or mortality in community-acquired pneumonia: Derivation and validation of a multivariable model.
Biomol Biomed, 24(2):337-345, 11 Mar 2024
Cited by: 1 article | PMID: 37795970 | PMCID: PMC10950343
Factors Associated with Hospitalized Community-Acquired Pneumonia among Elderly Patients Receiving Home-Based Care.
Healthcare (Basel), 12(4):443, 08 Feb 2024
Cited by: 1 article | PMID: 38391817 | PMCID: PMC10887704
ICU Utilization After Implementation of Minor Severe Pneumonia Criteria in Real-Time Electronic Clinical Decision Support.
Crit Care Med, 52(3):e132-e141, 29 Dec 2023
Cited by: 1 article | PMID: 38157205
Go to all (368) article citations
Other citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
Pharmacotherapy, 21(7 pt 2):89S-94S, 01 Jul 2001
Cited by: 8 articles | PMID: 11446524
Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin.
Clin Ther, 22(2):250-264, 01 Feb 2000
Cited by: 28 articles | PMID: 10743984
Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Curr Med Res Opin, 26(2):355-363, 01 Feb 2010
Cited by: 1 article | PMID: 19995325
Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care?
Pharmacoeconomics, 22(7):413-420, 01 Jan 2004
Cited by: 20 articles | PMID: 15137880
Review